Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;76(8):1081–1086. doi: 10.1038/bjc.1997.511

Immunohistochemical expression of SKALP/elafin in squamous cell carcinoma of the oesophagus.

S Yamamoto 1, H Egami 1, T Kurizaki 1, H Ohmachi 1, N Hayashi 1, T Okino 1, Y Shibata 1, J Schalkwijk 1, M Ogawa 1
PMCID: PMC2228093  PMID: 9376270

Abstract

In this study, the immunohistochemical expression of a new inducible elastase inhibitor, SKALP (skin-derived anti-leucoproteinase)/elafin, in the tissue of squamous cell carcinoma and uninvolved oesophageal mucosa was studied using a polyclonal rabbit anti-serum against SKALP/elafin. The results were compared with the immunohistochemical staining of proliferating cell nuclear antigen (PCNA) and the TUNEL assay in serial sections. In non-malignant oesophageal mucosa, the expression of SKALP/elafin was localized in the cells of the stratified zone overlying the PCNA-positive basal zone. In oesophageal cancer, the incidence of the expression was significantly related to the degree of the differentiation of the tumour. Characteristically, the expression was almost limited in tumour cell nests that had a clear squamous phenotype. In tumour cell nests, the expression of SKALP/elafin was localized in the cells overlying PCNA-expressing cells and no expression was found in the cells that expressed PCNA; DNA fragmentation was often observed in the same cell layers as those in which SKALP/elafin immunoreactivity was found. This enzyme inhibitor is speculated to be involved in the induction of the cell differentiation and apoptosis of human squamous cell carcinoma cells of the oesophagus.

Full text

PDF
1081

Images in this article

1083Figure 1
on p.1083
1083Figure 2
on p.1083
1083Figure 3
on p.1083
1084Figure 4
on p.1084

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Albini A., Melchiori A., Santi L., Liotta L. A., Brown P. D., Stetler-Stevenson W. G. Tumor cell invasion inhibited by TIMP-2. J Natl Cancer Inst. 1991 Jun 5;83(11):775–779. doi: 10.1093/jnci/83.11.775. [DOI] [PubMed] [Google Scholar]
  2. Alkemade H. A., Molhuizen H. O., van Vlijmen-Willems I. M., van Haelst U. J., Schalkwijk J. Differential expression of SKALP/Elafin in human epidermal tumors. Am J Pathol. 1993 Dec;143(6):1679–1687. [PMC free article] [PubMed] [Google Scholar]
  3. Baker M. S., Bleakley P., Woodrow G. C., Doe W. F. Inhibition of cancer cell urokinase plasminogen activator by its specific inhibitor PAI-2 and subsequent effects on extracellular matrix degradation. Cancer Res. 1990 Aug 1;50(15):4676–4684. [PubMed] [Google Scholar]
  4. Basset P., Bellocq J. P., Wolf C., Stoll I., Hutin P., Limacher J. M., Podhajcer O. L., Chenard M. P., Rio M. C., Chambon P. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature. 1990 Dec 20;348(6303):699–704. doi: 10.1038/348699a0. [DOI] [PubMed] [Google Scholar]
  5. Cajot J. F., Bamat J., Bergonzelli G. E., Kruithof E. K., Medcalf R. L., Testuz J., Sordat B. Plasminogen-activator inhibitor type 1 is a potent natural inhibitor of extracellular matrix degradation by fibrosarcoma and colon carcinoma cells. Proc Natl Acad Sci U S A. 1990 Sep;87(18):6939–6943. doi: 10.1073/pnas.87.18.6939. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. DeClerck Y. A., Perez N., Shimada H., Boone T. C., Langley K. E., Taylor S. M. Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res. 1992 Feb 1;52(3):701–708. [PubMed] [Google Scholar]
  7. Kobayashi H., Fujie M., Shinohara H., Ohi H., Sugimura M., Terao T. Effects of urinary trypsin inhibitor on the invasion of reconstituted basement membranes by ovarian cancer cells. Int J Cancer. 1994 May 1;57(3):378–384. doi: 10.1002/ijc.2910570315. [DOI] [PubMed] [Google Scholar]
  8. Kobayashi H., Gotoh J., Kanayama N., Hirashima Y., Terao T., Sugino D. Inhibition of tumor cell invasion through matrigel by a peptide derived from the domain II region in urinary trypsin inhibition. Cancer Res. 1995 May 1;55(9):1847–1852. [PubMed] [Google Scholar]
  9. Liotta L. A., Rao C. N., Wewer U. M. Biochemical interactions of tumor cells with the basement membrane. Annu Rev Biochem. 1986;55:1037–1057. doi: 10.1146/annurev.bi.55.070186.005133. [DOI] [PubMed] [Google Scholar]
  10. Liotta L. A., Steeg P. S., Stetler-Stevenson W. G. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell. 1991 Jan 25;64(2):327–336. doi: 10.1016/0092-8674(91)90642-c. [DOI] [PubMed] [Google Scholar]
  11. Liotta L. A., Tryggvason K., Garbisa S., Hart I., Foltz C. M., Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature. 1980 Mar 6;284(5751):67–68. doi: 10.1038/284067a0. [DOI] [PubMed] [Google Scholar]
  12. Molhuizen H. O., Alkemade H. A., Zeeuwen P. L., de Jongh G. J., Wieringa B., Schalkwijk J. SKALP/elafin: an elastase inhibitor from cultured human keratinocytes. Purification, cDNA sequence, and evidence for transglutaminase cross-linking. J Biol Chem. 1993 Jun 5;268(16):12028–12032. [PubMed] [Google Scholar]
  13. Nakajima M., Welch D. R., Belloni P. N., Nicolson G. L. Degradation of basement membrane type IV collagen and lung subendothelial matrix by rat mammary adenocarcinoma cell clones of differing metastatic potentials. Cancer Res. 1987 Sep 15;47(18):4869–4876. [PubMed] [Google Scholar]
  14. Reich R., Thompson E. W., Iwamoto Y., Martin G. R., Deason J. R., Fuller G. C., Miskin R. Effects of inhibitors of plasminogen activator, serine proteinases, and collagenase IV on the invasion of basement membranes by metastatic cells. Cancer Res. 1988 Jun 15;48(12):3307–3312. [PubMed] [Google Scholar]
  15. Schalkwijk J., Chang A., Janssen P., De Jongh G. J., Mier P. D. Skin-derived antileucoproteases (SKALPs): characterization of two new elastase inhibitors from psoriatic epidermis. Br J Dermatol. 1990 May;122(5):631–641. doi: 10.1111/j.1365-2133.1990.tb07285.x. [DOI] [PubMed] [Google Scholar]
  16. Schalkwijk J., de Roo C., de Jongh G. J. Skin-derived antileukoproteinase (SKALP), an elastase inhibitor from human keratinocytes. Purification and biochemical properties. Biochim Biophys Acta. 1991 Feb 22;1096(2):148–154. doi: 10.1016/0925-4439(91)90053-c. [DOI] [PubMed] [Google Scholar]
  17. Schalkwijk J., van Vlijmen I. M., Alkemade J. A., de Jongh G. J. Immunohistochemical localization of SKALP/elafin in psoriatic epidermis. J Invest Dermatol. 1993 Apr;100(4):390–393. doi: 10.1111/1523-1747.ep12471990. [DOI] [PubMed] [Google Scholar]
  18. Wiedow O., Lüademann J., Utecht B. Elafin is a potent inhibitor of proteinase 3. Biochem Biophys Res Commun. 1991 Jan 15;174(1):6–10. doi: 10.1016/0006-291x(91)90476-n. [DOI] [PubMed] [Google Scholar]
  19. Wiedow O., Schröder J. M., Gregory H., Young J. A., Christophers E. Elafin: an elastase-specific inhibitor of human skin. Purification, characterization, and complete amino acid sequence. J Biol Chem. 1990 Sep 5;265(25):14791–14795. [PubMed] [Google Scholar]
  20. Woolley D. E. Collagenolytic mechanisms in tumor cell invasion. Cancer Metastasis Rev. 1984;3(4):361–372. doi: 10.1007/BF00051460. [DOI] [PubMed] [Google Scholar]
  21. Zou Z., Anisowicz A., Hendrix M. J., Thor A., Neveu M., Sheng S., Rafidi K., Seftor E., Sager R. Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science. 1994 Jan 28;263(5146):526–529. doi: 10.1126/science.8290962. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES